We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Excess of Osteoclasts Causes Damage in Psoriatic Arthritis

By Biotechdaily staff writers
Posted on 28 Mar 2003
Researchers have found that blood samples from patients with psoriatic arthritis, particularly those with bone erosions visible on radiographs, exhibited a marked increase in osteoclast precursors (OCPs) compared with those from healthy controls and that these precursors gave rise to cells that caused bone destruction. More...
Their findings were published in the March 15, 2003, issue of the Journal of Clinical Investigation.

Approximately 10-15% of people who have psoriasis also develop psoriatic arthritis, usually between 20 and 30 years of age. Patients usually suffer from a great deal of joint pain, swelling, and inflammation. In the current study, investigators at the University of Rochester Medical Center (NY, USA) studied 30 patients with the disease and 12 healthy individuals to understand the events that lead to bone destruction. They analyzed blood samples and examined cells from the synovium, the joint lining that normally nourishes a joint but becomes invasive and destructive in patients with psoriatic arthritis.

They found that patients with psoriatic arthritis had 45 times more osteoclast precursors in their blood than did the controls. Eventually, these form osteoclasts that specialize in breaking down or eroding bone circulating in their bloodstream. Furthermore, patients had high amounts of the growth factor RANKL in their joints. RANKL stimulates osteoclast precursors to mature into full-fledged osteoclasts.

While a limited number of osteoclasts are required to maintain normal bone structure, in psoriatic arthritis there are too many of them. "We have found nests of osteoclasts deep within the bone, just perched and ready to attack. These are big monster cells, giants compared to other nearby cells. They appear to migrate toward the joint, where they do their damage,” explained first author Dr. Christopher T. Ritchlin, a rheumatologist at the University of Rochester Medical Center.

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Multi-Chamber Washer-Disinfector
WD 390
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.